Short answer
Mineralys Therapeutics, Inc. (MLYS) filed an 8-K current report with the SEC on June 3, 2026 reporting Item 8.01 (Other Events). $142.5 million expected net proceeds from sale of 5,660,378 common shares.
Mineralys Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- $142.5 million expected net proceeds from sale of 5,660,378 common shares
- Offering price $26.50 per share, with underwriters purchasing at $25.3075
- Approximately 5.7 million shares of dilution for existing shareholders
- Expected June 4, 2026 closing, subject to customary conditions
- Financing strengthens Mineralys’ capital resources, with deployment details in the accompanying prospectus materials
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Mineralys Therapeutics, Inc. 8-K filings
Get the next MLYS 8-K as it lands
Follow MLYS for push alerts, or ask the research agent what this filing means.